The aforementioned study suffered from several problems: patients presenting de novo IPSS6 low or intermediate‐1 MDS, with Hb ≤10.0 g/dL could be enrolled even if they were transfusion dependent. This evidence concerns the gene GSTM1 and myelodysplastic syndrome.